Madrigal Pharmaceuticals

Conshohocken, United States Founded: 2011 • Age: 15 yrs Listed Acquired By Synta Pharmaceuticals
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a publicly listed company based in Conshohocken (United States) founded in 2011, and was acquired by Synta Pharmaceuticals in April 2016. It develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis. Madrigal Pharmaceuticals has raised $38.38 million across 2 funding rounds from investors including Madrigal. The company has 528 employees. Its website madrigalpharma.com draws about 54 thousand monthly visits. Madrigal Pharmaceuticals offers products and services including Rezdiffra. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.

Company details

Madrigal Pharmaceuticals was founded in 2011 and is headquartered in Conshohocken, United States. Operations are centered on the development of small molecule therapeutics targeting cardiovascular and metabolic diseases, including non-alcoholic steatohepatitis. The company focuses on advancing drug candidates through clinical stages within the biopharmaceutical sector, with activities spanning research, preclinical testing, and regulatory processes in the United States.

  • Headquarters Conshohocken, United States
  • Employees 528
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website madrigalpharma.com
  • Social LinkedIn X
  • Acquired by Synta Pharmaceuticals (Apr 2016)
  • Legal Name Madrigal Pharmaceuticals, Inc.
Key Metrics
  • Annual Revenue
    $958.4 M (USD)
    432.05
    as on Dec 31, 2025
  • Net Profit
    -$288.28 M (USD)
    38.12
    as on Dec 31, 2025
  • EBITDA
    -$298.59 M (USD)
    39.89
    as on Dec 31, 2025
  • Total Equity Funding
    $38.38M (USD)

    in 2 rounds

  • Latest Funding Round
    $35M (USD), Series A

    Jun 2017

  • Investors
  • Employee Count
    528
  • Acquired by

Products & Services of Madrigal Pharmaceuticals

Madrigal Pharmaceuticals offers a comprehensive portfolio of products and services, including Rezdiffra.

Rezdiffra
Pharmaceutical Drug

Treats NASH with moderate to advanced liver fibrosis.

Funding Insights of Madrigal Pharmaceuticals

Madrigal Pharmaceuticals has successfully raised a total of $38.38M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $35 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $38.38M
  • Total Rounds 2
  • Last Round Series A β€” $35M
  • First Round $3.38M

    (Apr 2016)

All 2 funding rounds of Madrigal Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2017$35MSeries A––
–
Apr 2016$3.38MSeries A––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Madrigal Pharmaceuticals

Madrigal Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Madrigal.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Small molecule drugs are developed for cancer and inflammatory diseases.
2000syntapharma.comLexington, United States
Premium access

Investor details for Madrigal Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Madrigal Pharmaceuticals

288 people are tracked at Madrigal Pharmaceuticals (142 in leadership, 6 in board & advisors, 140 in team); the tracked headcount is 528.

NameRoleGroup
Hetal Panchal
Sr. Director, Data Platform And AnalyticsLeadership
Jason Gay
Regional Business DirectorLeadership
Ron Marchessault
Vice President, Head Of Market AccessLeadership
Kristine Grigoryan
Payroll DirectorLeadership
Zara Gaudioso
Director Human Resources OperationsLeadership
Parth Patel
Executive Director, AI And Data ScienceLeadership
Nancy B.
Director, Commercial Training & DevelopmentLeadership
Christopher Milazzo
Sr. Director, Clinical Practice LiaisonsLeadership
Vanessa MacGregor
Director, Specialty Pharmacy: Market AccessLeadership
Amir Karimzadeh
Senior Director -nash Medical SciencesLeadership
Scott Farris
Sr Director, Health Systems National AccountsLeadership
Ken Liu
Senior Director, National Accounts, US Market AccessLeadership
Brad Giglio
Senior Director National AccountsLeadership
Amber Pace
Northeast Regional Sales DirectorLeadership
John O'Donnell
Vice President, Global Health Economics And Outcomes ResearchLeadership
Carlos Blocker
Regional Sales DirectorLeadership
Lauren van Den Heuvel
Senior Director, Market Access Strategy & OperationsLeadership
Alexandre Felizardo
Executive Director- Market AccessLeadership
Bob O'Rourke
Vice President, Talent AccessLeadership
Kelley Anne Bruni
Director, Key Accounts, Health SystemsLeadership

268 more people are available in the full profile.

Premium access

Complete people profiles for Madrigal Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol MDGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date07 Nov 2013
  • Listed onNASDAQ: MDGL
  • Listed entityMadrigal Pharmaceuticals, Inc.
  • Exchange sectorHealth technology
  • ISINUS5588681057
  • Share price$452.12 (-3.22% on the day) · 2026-10-13
  • Market capitalisation$10.45B
  • EPS (diluted, trailing year)$-12.88
  • Volume (last session)315,930

Financials of Madrigal Pharmaceuticals

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$958.4M-$288.3M-$298.6M
2024$180.1M-$465.9M-$496.8M
2023-$373.6M-$380.0M
2022-$295.4M-$293.1M
2021-$241.8M-$241.6M
Premium access

Detailed financial statements for Madrigal Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Madrigal Pharmaceuticals

5 dated milestones of Madrigal Pharmaceuticals across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Madrigal Pharmaceuticals is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Exit Acquired by Synta Pharmaceuticals.
  4. Funding First funding round of $3.4M.
  5. Funding Latest funding round, Series A, of $35.0M.

Competitors of Madrigal Pharmaceuticals

Madrigal Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
ngmbio.com2007San Francisco, United States$358.87M225
Biologics are developed for cardio-metabolic and liver diseases.
nimbustx.com2009Cambridge, United States$685M81
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
altimmune.com1997Gaithersburg, United States$58M17
Vaccines for infectious diseases and solid tumors are developed.
Premium access

Detailed competitors of Madrigal Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Madrigal Pharmaceuticals

The website of Madrigal Pharmaceuticals (madrigalpharma.com) receives about 54.4K visits a month and ranks #889,142 among all websites worldwide, #1,070 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    54.4K

    ▲ 50.5% vs previous month

  • Unique visitors
    15.5K

    per month

  • Global rank
    #889,142

    among all websites

  • Category rank
    #1,070

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Madrigal Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
briacell.com
100%
8.1K#2,386,302View details
portola.com
98%
View details
phasebio.com
98%
2.2K#11,529,454View details
nexgenixpharm.com
97%
View details
deciphera.com
97%
12.2K#2,044,202View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 27 similar websites and full traffic analytics for Madrigal Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 27 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Metabolic Diseases

3 companies that operate in the same segment as Madrigal Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
2010Boston, Massachusetts, United StatesUSD 84 MUSD 189.76 M283
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Madrigal Pharmaceuticals

Premium access

Complete news archive for Madrigal Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Madrigal Pharmaceuticals

Madrigal Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.

Madrigal Pharmaceuticals is headquartered in Conshohocken, United States. It is registered at Conshohocken, Pennsylvania, United States.

Madrigal Pharmaceuticals is a funded company, having raised a total of $38.38M across 2 funding rounds to date. The company's 1st funding round was a Series A of $3.38M, raised on Apr 2016.

Madrigal Pharmaceuticals has 528 employees.

Annual revenue of Madrigal Pharmaceuticals is $958.4M as on Dec 31, 2025.

Madrigal Pharmaceuticals was founded in 2011 and is headquartered in Conshohocken, United States. Operations are centered on the development of small molecule therapeutics targeting cardiovascular and metabolic diseases, including non-alcoholic steatohepatitis. The company focuses on advancing drug candidates through clinical stages within the biopharmaceutical sector, with activities spanning research, preclinical testing, and regulatory processes in the United States.

Madrigal Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.

Madrigal Pharmaceuticals offers Rezdiffra.

Yes, Madrigal Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol MDGL.

Madrigal Pharmaceuticals has 1 investor. Key investors include Madrigal.

Yes. Madrigal Pharmaceuticals was acquired by Synta Pharmaceuticals in April 2016.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available